UCB S.A.
UCB
Rank in Stocks
#523
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Share Price
$242.33
Last synced: 2026-10-19
Market Cap
$46.20B
Change (1 day)
-0.15%
Change (1 year)
-17.83%
Country
BE
Trade UCB S.A. (UCB)
Category
Healthcare
P/E ratio for UCB S.A. (UCB)
P/E ratio as of October 2026 TTM: 17.49
According to UCB S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.49. At the end of 2023 the company had a P/E ratio of 43.79.
P/E ratio history for UCB S.A. from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 17.49 | -48.97% |
| 2024 | 34.27 | -21.74% |
| 2023 | 43.79 | 31.23% |
| 2022 | 33.37 | 86.17% |
| 2021 | 17.92 | -17.84% |
| 2020 | 21.82 | 30.17% |
| 2019 | 16.76 | -0.23% |
| 2018 | 16.80 | 0.45% |
| 2017 | 16.72 | -24.21% |
| 2016 | 22.06 | -63.56% |
| 2015 | 60.56 | -42.14% |
| 2014 | 104.67 | -12.97% |
| 2013 | 120.27 | 297.35% |
| 2012 | 30.27 | 14.24% |
| 2011 | 26.49 | -40.42% |
| 2010 | 44.47 | 334.11% |
| 2009 | 10.24 | -89.51% |
| 2008 | 97.63 | 181.23% |
| 2007 | 34.71 | 69.86% |
| 2006 | 20.44 | 170.96% |
| 2005 | 7.54 | -49.31% |
| 2004 | 14.88 | 15.88% |
| 2003 | 12.84 | -21.17% |
| 2002 | 16.29 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 64.57% |
US
|
|
| -28.36 | -262.15% |
US
|
|
| -24.57 | -240.47% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 73.42% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.